U.S. markets closed

Tricida, Inc. (TCDA)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
4.8500-0.0900 (-1.82%)
At close: 4:00PM EDT

Tricida, Inc.

7000 Shoreline Court
Suite 201
South San Francisco, CA 94080
United States
415 429 7800

Full Time Employees64

Key Executives

NameTitlePayExercisedYear Born
Dr. Gerrit KlaernerFounder, Pres, CEO & Exec. Director719.98kN/A1971
Mr. Geoffrey M. ParkerCOO, CFO & Exec. VP502.33kN/A1965
Dr. Wilhelm StahlExec. VP & CTO472.06k18.61k1960
Mr. Robert L. McKague J.D.Exec. VP, Company Sec., Gen. Counsel & Chief Compliance Officer486.46kN/AN/A
Dr. Dawn Parsell Ph.D.Exec. VP of Clinical Devel.504.92k666.12k1962
Ms. Annie YoshiyamaVP of Fin. & Chief Accounting OfficerN/AN/A1983
Jackie CossmonVP of Investor Relations & CommunicationsN/AN/AN/A
Mr. Edward J. Hejlek Esq., J.D.Exec. VP of Intellectual PropertyN/AN/A1957
Mr. Marc CoboConsultantN/AN/A1980
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of TRC101, a non-absorbed orally-administered polymer that has completed phase 3 trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

Corporate Governance

Tricida, Inc.’s ISS Governance QualityScore as of June 1, 2021 is 9. The pillar scores are Audit: 2; Board: 5; Shareholder Rights: 9; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.